Role of complement activation in hypersensitivity reactions to doxil and HYNICPEG liposomes: Experimental and clinical studies

被引:167
作者
Szebeni, J [1 ]
Baranyi, L
Savay, S
Milosevits, J
Bunger, R
Laverman, P
Metselaar, JM
Storm, G
Chanan-Khan, A
Liebes, L
Muggia, FM
Cohen, R
Barenholz, Y
Alving, CR
机构
[1] Walter Reed Army Inst Res, Silver Spring, MD USA
[2] Uniformed Serv Univ Hlth Sci, Dept Anatomy Physiol & Genet, Bethesda, MD USA
[3] Univ Nijmegen, Ctr Med, Dept Nucl Med, Nijmegen, Netherlands
[4] Univ Utrecht, Utrecth Inst Pharmaceut Sci, Utrecht, Netherlands
[5] NYU, Ctr Med, Kaplan Comprehens Canc Ctr, New York, NY USA
[6] Hebrew Univ Jerusalem, Hadassah Med Sch, Lab Membrane & Liposome Res, Jerusalem, Israel
关键词
D O I
10.1081/LPR-120004790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pegylated liposomal doxorubicin (Doxil) and Tc-99m-HYNIC PEG liposomes (HPL) were reported earlier to cause hypersensitivity reactions (HSRs) in a substantial percentage of patients treated i.v. with these formulations. Here we report that (1) Doxil, HPL, pegylated phosphatidylethanolamine (PEG-PE)-containing empty liposomes matched with Doxil and HPL in size and lipid composition, and phosphatidylglycerol (PG)-containing negatively charged vesicles were potent C activators in human serum in vitro, whereas small neutral liposomes caused no C activation. (2) Doxil and other size-matched PEG-PE and/or PG-containing liposomes also caused massive cardiopulmonary distress with anaphylactoid shock in pigs via C activation, whereas equivalent neutral liposomes caused no hemodynamic changes. (3) A clinical study showed more frequent and greater C activation in patients displaying HSR than in non-reactive patients. These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 18 条
[1]   Safety aspects of pegylated liposomal doxorubicin in patients with cancer [J].
Alberts, DS ;
Garcia, DJ .
DRUGS, 1997, 54 (Suppl 4) :30-35
[2]   Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease [J].
Brouwers, AH ;
De Jong, DJ ;
Dams, ETM ;
Oyen, WJG ;
Boerman, OC ;
Laverman, P ;
Naber, THJ ;
Storm, G ;
Corstens, FHM .
JOURNAL OF DRUG TARGETING, 2000, 8 (04) :225-233
[3]  
deMarie S, 1996, LEUKEMIA, V10, pS93
[4]  
Dezube BJ, 1996, DOXIL CLIN SERIES, V1, P1
[5]  
GABIZON A, 1994, CANCER RES, V54, P987
[6]   CLINICAL-STUDIES OF LIPOSOME-ENCAPSULATED DOXORUBICIN [J].
GABIZON, A ;
ISACSON, R ;
LIBSON, E ;
KAUFMAN, B ;
UZIELY, B ;
CATANE, R ;
BENDOR, CG ;
RABELLO, E ;
CASS, Y ;
PERETZ, T ;
SULKES, A ;
CHISIN, R ;
BARENHOLZ, Y .
ACTA ONCOLOGICA, 1994, 33 (07) :779-786
[7]  
Gabizon A.A., 1998, LONG CIRCULATING LIP, P155
[8]   Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy [J].
Gabizon, AA .
CANCER INVESTIGATION, 2001, 19 (04) :424-436
[9]   Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer [J].
Koukourakis, MI ;
Koukouraki, S ;
Giatromanolaki, A ;
Archimandritis, SC ;
Skarlatos, J ;
Beroukas, K ;
Bizakis, JG ;
Retalis, G ;
Karkavitsas, N ;
Helidonis, ES .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3512-3521
[10]  
Lyass O, 2001, CLIN CANCER RES, V7, P3040